Total
0
Shares
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon
Managing Director, Fleta Solomon
Source: LGP
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) successfully imports its first shipment of cannabis flower medicines to Australia from its Danish facility
  • This shipment consists of around 50 kilograms of LGP’s Flower THC 16 — Billy Buttons flower medicine
  • Billy Buttons THC 16 has a THC content of 16 per cent and is available for sale in all Australian pharmacies in 15-gram packs
  • Additionally, Little Green Pharma has appointed Morten Snede as Chief Financial Officer and Tony Roberts as General Manager EU
  • Little Green Pharma is up 3.38 per cent on the market with shares trading at 76.5 cents at 2:07 pm AEST

Little Green Pharma (LGP) has successfully imported its first shipment of cannabis flower medicines to Australia from its Danish facility.

This shipment consists of around 50 kilograms of LGP’s Flower THC 16 — Billy Buttons flower medicine which is named after the Australian wildflower.

Billy Buttons THC 16 has a THC content of 16 per cent and is available for sale in all Australian pharmacies in 15-gram packs.

Little Green Pharma expects two additional shipments of its cannabis flower medicines by the end of October.

This shipment comes at a time when more Australian doctors become comfortable with administering dried flower medicine to their patients.

Managing Director Fleta Solomon is excited by this first shipment.

“The import of this first shipment so quickly following the acquisition is a milestone achievement by our new Denmark team,” Ms Solomon commented.

“To be able to meet all the regulatory requirements to supply and import product within this timeframe is a significant achievement and consistent with our reputation as a leading global medicinal cannabis business.”

Additionally, Little Green Pharma has appointed Morten Snede as Chief Financial Officer (CFO) and Tony Roberts as General Manager EU.

Mr Snede has over 20 years of experience in senior managerial positions across the financial and maritime industries, working as both CFO and Group Director.

Prior to joining Little Green Pharma, he was Managing Director at Canopy Growth.

Mr Roberts has over 34 years of experience in an Australian agribusiness with 20 years as a senior corporate executive in financial services, strategic planning, IT design and business acquisition.

He has previously worked as Managing Director of Tasmanian Botanics.

Little Green Pharma was up 3.38 per cent on the market with shares trading at 76.5 cents at 2:07 pm AEST.

LGP by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.